GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 09:40:31 2024-07-08 EDT 5-day change 1st Jan Change
1,515 GBX +0.25% Intraday chart for GSK plc -0.72% +4.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
That's not so bad, is it? Our Logo
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment MT
UBS Downgrades GSK to Neutral from Buy, Cuts PT MT
ITeos Therapeutics, Inc. Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK CI
UBS cuts GSK; RBC raises Melrose Industries AN
GSK : UBS downgrades its recommendation CF
Carlsberg to buy Britvic in GBP3.3 billion deal AN
GSK : Reduced to Neutral by UBS ZD
GSK: FIRST SINGLE-DOSE MEDICINE TO PREVENT RELAPSE OF P. VIVAX M… RE
GSK launches antimalarial drug in Thailand and Brazil CF
Citigroup Trims GSK PT, Maintains Buy Rating MT
Jefferies cuts Softcat to 'underperform' AN
GSK : Deutsche Bank keeps its Buy rating ZD
GSK : UBS keeps its Buy rating ZD
Health Stocks Slip in Risk-On Trade -- Health Care Roundup DJ
Sector Update: Health Care Stocks Fall in Afternoon Trading MT
Sector Update: Health Care MT
European Equities Close Higher in Wednesday Trading; Euro Area Growth Slows to 3-Month Low MT
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday MT
Looming Holiday Break Stifles US Equity Futures Pre-Bell MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge MT
GSK to Buy COVID-19, Flu Vaccine Rights From CureVac for $1.56 Billion MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion -- 2nd Update DJ
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.11 GBP
Average target price
19.96 GBP
Spread / Average Target
+32.08%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. Citigroup Trims GSK PT, Maintains Buy Rating